Germany covid-19 vaccine symptomatic Germany

COVID-19 vaccine trial complete, Pfizer and BioNTech update their promising result

Reading now: 496
www.sciencemag.org

Jon CohenScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.Not to be outdone by a rival with a similar product, Pfizer and BioNTech today provided an update on the previously announced success of their COVID-19 vaccine.

The U.S. pharma giant and its German biotech partner now report 95% efficacy for their vaccine candidate, drawing on the final analysis of a 43,000-person study.

And don’t worry about the elderly not responding to the vaccine; the efficacy only drops to 94% in people over 65 years of age, the companies said in a press release.As opposed to the vague initial report last week that their vaccine had greater than 90% efficacy, Pfizer and BioNTech are providing more specific data.

Read more on sciencemag.org
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA